• Evolva Holdings SA, of Reinach, Switzerland, said top-line results for the first 32 patients enrolled in the Phase IIa study testing EV-077, a reversible antagonist of isoprostanes and prostanoids, showed promising efficacy, indicating that the drug, when given orally twice daily to patients with Type II diabetes, provided antiplatelet activity, reduced exercise-induced proteinuria and increased forearm blood flow. Read More
• Ranbaxy Pharmaceuticals Inc., of Princeton, N.J., said it launched an authorized generic version of pioglitazone hydrochloride tablets in the U.S. market, under an agreement with Takeda Pharmaceuticals Ltd., of Osaka, Japan. Read More
• BioSante Pharmaceuticals Inc., of Lincolnshire, Ill., said it received a commitment from an institutional investor to purchase about $3.5 million of securities in a registered direct offering. Read More
By using a forward genetics approach, two separate teams of researchers have identified related genes as potential oncogenes and mediators of receptor tyrosine kinase inhibitors. Read More
As the Trans-Pacific Partnership (TPP) talks head into their 14th round early next month, U.S. lawmakers continue to press the president to ensure the negotiations protect the 12-year data exclusivity for biologics. Read More
A report produced by the George Washington University School of Public Health found that prescription drugs could fill a critical treatment gap for obese patients who do not respond to lifestyle interventions and are not candidates for bariatric surgery. Read More
